GRTX logo

Galera Therapeutics (GRTX) Cash From Operations

Annual CFO

-$44.85 M
-$1.42 M-3.27%

31 December 2023

GRTX Cash From Operations Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly CFO

-$2.30 M
+$419.00 K+15.42%

01 September 2024

GRTX Quarterly CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM CFO

-$19.72 M
+$10.22 M+34.14%

01 September 2024

GRTX TTM CFO Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

GRTX Cash From Operations Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-+76.8%+56.0%
3 y3 years+34.0%+86.8%+71.0%
5 y5 years+3.9%+85.0%+57.7%

GRTX Cash From Operations High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 years-3.3%+34.0%at high+86.8%at high+71.0%
5 y5 years-3.3%+34.0%at high+87.5%at high+71.0%
alltimeall time-102.3%+34.0%at high+87.5%-120.9%+71.0%

Galera Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sept 2024
-
-$2.30 M(-15.4%)
-$19.72 M(-34.1%)
June 2024
-
-$2.72 M(-43.3%)
-$29.94 M(-21.1%)
Mar 2024
-
-$4.79 M(-51.7%)
-$37.97 M(-15.3%)
Dec 2023
-$44.85 M(+3.3%)
-$9.91 M(-20.8%)
-$44.85 M(-8.2%)
Sept 2023
-
-$12.52 M(+16.5%)
-$48.88 M(+7.3%)
June 2023
-
-$10.75 M(-7.9%)
-$45.57 M(+4.3%)
Mar 2023
-
-$11.67 M(-16.3%)
-$43.71 M(+0.6%)
Dec 2022
-$43.43 M(-36.1%)
-$13.95 M(+51.4%)
-$43.43 M(-7.5%)
Sept 2022
-
-$9.21 M(+3.6%)
-$46.93 M(-16.4%)
June 2022
-
-$8.89 M(-21.9%)
-$56.12 M(-12.4%)
Mar 2022
-
-$11.38 M(-34.7%)
-$64.04 M(-5.8%)
Dec 2021
-$67.96 M
-$17.45 M(-5.2%)
-$67.96 M(+1.5%)
DateAnnualQuarterlyTTM
Sept 2021
-
-$18.40 M(+9.5%)
-$66.96 M(+4.9%)
June 2021
-
-$16.80 M(+9.8%)
-$63.84 M(+2.2%)
Mar 2021
-
-$15.30 M(-7.0%)
-$62.45 M(+4.9%)
Dec 2020
-$59.54 M(+27.6%)
-$16.45 M(+7.6%)
-$59.54 M(+2.0%)
Sept 2020
-
-$15.28 M(-0.8%)
-$58.36 M(+4.3%)
June 2020
-
-$15.41 M(+24.4%)
-$55.98 M(+11.7%)
Mar 2020
-
-$12.39 M(-18.9%)
-$50.12 M(+7.4%)
Dec 2019
-$46.66 M(+110.5%)
-$15.28 M(+18.4%)
-$46.66 M(+48.7%)
Sept 2019
-
-$12.90 M(+35.0%)
-$31.39 M(+69.8%)
June 2019
-
-$9.55 M(+7.0%)
-$18.48 M(+107.0%)
Mar 2019
-
-$8.93 M
-$8.93 M
Dec 2018
-$22.17 M(-5.3%)
-
-
Dec 2017
-$23.41 M
-
-

FAQ

  • What is Galera Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Galera Therapeutics?
  • What is Galera Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Galera Therapeutics?
  • What is Galera Therapeutics quarterly CFO year-on-year change?
  • What is Galera Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Galera Therapeutics?
  • What is Galera Therapeutics TTM CFO year-on-year change?

What is Galera Therapeutics annual cash flow from operations?

The current annual CFO of GRTX is -$44.85 M

What is the all time high annual CFO for Galera Therapeutics?

Galera Therapeutics all-time high annual cash flow from operations is -$22.17 M

What is Galera Therapeutics quarterly cash flow from operations?

The current quarterly CFO of GRTX is -$2.30 M

What is the all time high quarterly CFO for Galera Therapeutics?

Galera Therapeutics all-time high quarterly cash flow from operations is -$2.30 M

What is Galera Therapeutics quarterly CFO year-on-year change?

Over the past year, GRTX quarterly cash flow from operations has changed by +$7.62 M (+76.82%)

What is Galera Therapeutics TTM cash flow from operations?

The current TTM CFO of GRTX is -$19.72 M

What is the all time high TTM CFO for Galera Therapeutics?

Galera Therapeutics all-time high TTM cash flow from operations is -$8.93 M

What is Galera Therapeutics TTM CFO year-on-year change?

Over the past year, GRTX TTM cash flow from operations has changed by +$25.13 M (+56.03%)